American Association for Cancer Research
10780432ccr141337-sup-132125_1_supp_2588694_n9j8wy.pptx (909.44 kB)

Figure S2 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma

Download (909.44 kB)
posted on 2023-03-31, 18:30 authored by Marzia Capelletti, Michael E. Dodge, Dalia Ercan, Peter S. Hammerman, Seung-Il Park, Jhingook Kim, Hidefumi Sasaki, David M. Jablons, Doron Lipson, Lauren Young, Phil J. Stephens, Vincent A. Miller, Neal I. Lindeman, Kiara J. Munir, William G. Richards, Pasi A. Jänne

Figure S2. Haematoxylin and eosin staining of two patient samples with adenocarcinoma histology: A. CG-42. B. J2-109.



Purpose: Targetable oncogenic alterations are detected more commonly in patients with non–small cell lung cancer (NSCLC) who never smoked cigarettes. For such patients, specific kinase inhibitors have emerged as effective clinical treatments. However, the currently known oncogenic alterations do not account for all never smokers who develop NSCLC. We sought to identify additional oncogenic alterations from patients with NSCLC to define additional treatment options.Experimental Design: We analyzed 576 lung adenocarcinomas from patients of Asian and Caucasian ethnicity. We identified a subset of cancers that did not harbor any known oncogenic alteration. We performed targeted next-generation sequencing (NGS) assay on 24 patients from this set with >75% tumor cell content.Results:EGFR mutations were the most common oncogenic alteration from both Asian (53%) and Caucasian (41.6%) patients. No known oncogenic alterations were present in 25.7% of Asian and 31% of Caucasian tumor specimens. We identified a FGFR3–TACC3 fusion event in one of 24 patients from this subset using targeted NGS. Two additional patients harboring FGFR3–TACC3 were identified by screening our entire cohort (overall prevalence, 0.5%). Expression of FGFR3–TACC3 led to IL3 independent growth in Ba/F3 cells. These cells were sensitive to pan-fibroblast growth factor receptor (pan-FGFR) inhibitors but not the epidermal growth factor (EGFR) inhibitor gefitinib.Conclusions:FGFR3–TACC3 rearrangements occur in a subset of patients with lung adenocarcinoma. Such patients should be considered for clinical trials featuring FGFR inhibitors. Clin Cancer Res; 20(24); 6551–8. ©2014 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager